User:Abhirupa 2000/Choose an Article

Article Selection
Please list articles that you're considering for your Wikipedia assignment below. Begin to critique these articles and find relevant sources.

Option 1

 * Epigenetics of neurodegenerative diseases
 * Article Evaluation
 * The warning at the top of the page says that this article relies too heavily on primary research sources, which should be fixed by referencing more review articles that perhaps incorporate the primary research sources in the current article.
 * A potential source of revision could be the table that summarizes the results of several experimental trials for epigenetic drug therapies to treat a variety of neurodegenerative diseases. Currently, it is difficult to make much sense of the table and the legend doesn't really provide much assistance to deciphering the significance of each row and column and their intersections. Also, most of the entries in the table come from primary sources the therapeutic effect of a particular drug on neurodegernative diseases like ALS, Alzheimer's, Huntington's, etc. It would likely be more appropriate to reference review articles that have consolidated the results of several experimental trials and could provide a more comprehensive overview of potential therapies.
 * In general, most of the sources are about a decade old. Since epigenetics and neurodegenerative disease is quite an active area of study, there are likely more current sources that could help round out the content in this article
 * Sources
 * Nikolac Perkovic, Matea et al. “Epigenetics of Alzheimer's Disease.” Biomolecules vol. 11,2 195. 30 Jan. 2021, doi:10.3390/biom1102019
 * Lardenoije, Roy et al. “The epigenetics of aging and neurodegeneration.” Progress in neurobiology vol. 131 (2015): 21-64. doi:10.1016/j.pneurobio.2015.05.002
 * Zhu, Guizhi, and Xiaoyuan Chen. “Aptamer-based targeted therapy.” Advanced drug delivery reviews vol. 134 (2018): 65-78. doi:10.1016/j.addr.2018.08.005
 * Lardenoije, Roy et al. “The epigenetics of aging and neurodegeneration.” Progress in neurobiology vol. 131 (2015): 21-64. doi:10.1016/j.pneurobio.2015.05.002
 * Zhu, Guizhi, and Xiaoyuan Chen. “Aptamer-based targeted therapy.” Advanced drug delivery reviews vol. 134 (2018): 65-78. doi:10.1016/j.addr.2018.08.005

Option 2

 * Epigenetic therapy
 * Article Evaluation
 * There are a few warnings listed for this page. It contains many primary sources and is suspected to contain original research. I think one of the sections that may contain this original research is the Fear, Anxiety, and Trauma section. This sentence in particular--"The most likely explanation is that exposure therapy works by a learning process, and can be enhanced by processes which increase neural plasticity and learning."--makes me think that the editor may have summarized the findings of a particular review too liberally. This section also contains phrases like "increases anxiety significantly" but it doesn't include a metric by which these qualitative statements are being made.
 * The schizophrenia section is also a bit perfunctory and reflective, especially the sentence that says "Even if epigenetic therapy wouldn't allow to fully reverse the disease, it can significantly improve the quality of life." This sentence seems to have been drawn from a review in a medical journal, but I think there should be more discussion of this claim and the supporting evidence that the review authors provided to back up this assertion--if it was even stated as such in the review article.
 * This article is also pretty sparse in the applications of epigenetic therapy. In my research for the previous article, I found lots of evidence to suggest that many researchers are looking into epigenetic therapy for neurodegerative diseases; there is no section for this topic in this article though. I think there should at least be a short blurb and a link to the "epigenetics of neurodegenerative diseases" article.
 * Sources
 * Zhu, Guizhi, and Xiaoyuan Chen. “Aptamer-based targeted therapy.” Advanced drug delivery reviews vol. 134 (2018): 65-78. doi:10.1016/j.addr.2018.08.00
 * Jones, Peter A et al. “Epigenetic therapy in immune-oncology.” Nature reviews. Cancer vol. 19,3 (2019): 151-161. doi:10.1038/s41568-019-0109-9
 * Walton, Emma L. “On the road to epigenetic therapy.” Biomedical journal vol. 39,3 (2016): 161-5. doi:10.1016/j.bj.2016.08.005
 * Jones, Peter A et al. “Epigenetic therapy in immune-oncology.” Nature reviews. Cancer vol. 19,3 (2019): 151-161. doi:10.1038/s41568-019-0109-9
 * Walton, Emma L. “On the road to epigenetic therapy.” Biomedical journal vol. 39,3 (2016): 161-5. doi:10.1016/j.bj.2016.08.005

Option 3

 * Non-coding RNA
 * Article Evaluation
 * The banner at the top of the article indicated that themain problem with this article was that the lead was too short and should give a better preview of the topics covered throughout the article. There could definitely be a little more explanation of the functions of the different types of ncRNA that are listed in the first paragraph.
 * There are also a few sections, like the Genome Defense and cis-Acting sections, that require citations for the information referenced. The section entitled "In pathogenic avoidance" is perfunctory and could either be deleted altogether or added to a different section.
 * Some of the "Roles in Disease" subsections rely quite heavily on primary research, especially the section about Autism.
 * Sources
 * Kosillo, Polina, and Helen S Bateup. “Dopaminergic Dysregulation in Syndromic Autism Spectrum Disorders: Insights From Genetic Mouse Models.” Frontiers in neural circuits vol. 15 700968. 23 Jul. 2021, doi:10.3389/fncir.2021.700968 (a secondary review source that could be a better reference for the autism section)
 * Slack, Frank J, and Arul M Chinnaiyan. “The Role of Non-coding RNAs in Oncology.” Cell vol. 179,5 (2019): 1033-1055. doi:10.1016/j.cell.2019.10.017
 * Matsui, Masayuki, and David R Corey. “Non-coding RNAs as drug targets.” Nature reviews. Drug discovery vol. 16,3 (2017): 167-179. doi:10.1038/nrd.2016.117
 * Slack, Frank J, and Arul M Chinnaiyan. “The Role of Non-coding RNAs in Oncology.” Cell vol. 179,5 (2019): 1033-1055. doi:10.1016/j.cell.2019.10.017
 * Matsui, Masayuki, and David R Corey. “Non-coding RNAs as drug targets.” Nature reviews. Drug discovery vol. 16,3 (2017): 167-179. doi:10.1038/nrd.2016.117

Option 4

 * Centric Heterochromatin
 * Article Evaluation
 * This article is very short and the last edit was made about 6 years ago. There is only one citation, which is a few pages from a biology textbook. There wasn't much effort in making this article easily understandable to the layman. This article also doesn't delve into the significance of this topic very well; the question "why is centric heterochromatin important?" is not answered.
 * There were also not that many review sources that were specific to centric heterochromatin, so it might be worthwhile to just condense this into a section in the heterochromatin article.
 * Sources
 * Carone, Dawn M, and Jeanne B Lawrence. “Heterochromatin instability in cancer: from the Barr body to satellites and the nuclear periphery.” Seminars in cancer biology vol. 23,2 (2013): 99-108. doi:10.1016/j.semcancer.2012.06.008 (what kind of research has been done about centric heterochromatin)
 * Sources
 * Carone, Dawn M, and Jeanne B Lawrence. “Heterochromatin instability in cancer: from the Barr body to satellites and the nuclear periphery.” Seminars in cancer biology vol. 23,2 (2013): 99-108. doi:10.1016/j.semcancer.2012.06.008 (what kind of research has been done about centric heterochromatin)

Option 5

 * Gene dosage
 * Article Evaluation
 * This article is quite short and the references don't reflect much new knowledge. The topic of Down syndrome is mentioned in passing, but I think it warrants a subsection since deviations in chromosome copy number are directly linked to Down syndrome.
 * There could also be section about disorders like Turner syndrome and Klinefelter syndrome that have also been linked to gene dosage.
 * Sources
 * Basilicata, M Felicia, and Claudia Isabelle Keller Valsecchi. “The good, the bad, and the ugly: Evolutionary and pathological aspects of gene dosage alterations.” PLoS genetics vol. 17,12 e1009906. 9 Dec. 2021, doi:10.1371/journal.pgen.1009906 (gives an evolutionary analysis of the importance of gene dosage in humans and the various pathologies that arise due to gene dosage deficiencies)
 * Davies, William. “The contribution of Xp22.31 gene dosage to Turner and Klinefelter syndromes and sex-biased phenotypes.” European journal of medical genetics vol. 64,4 (2021): 104169. doi:10.1016/j.ejmg.2021.104169
 * Veitia, Reiner A et al. “Aging: Somatic Mutations, Epigenetic Drift and Gene Dosage Imbalance.” Trends in cell biology vol. 27,4 (2017): 299-310. doi:10.1016/j.tcb.2016.11.006
 * Davies, William. “The contribution of Xp22.31 gene dosage to Turner and Klinefelter syndromes and sex-biased phenotypes.” European journal of medical genetics vol. 64,4 (2021): 104169. doi:10.1016/j.ejmg.2021.104169
 * Veitia, Reiner A et al. “Aging: Somatic Mutations, Epigenetic Drift and Gene Dosage Imbalance.” Trends in cell biology vol. 27,4 (2017): 299-310. doi:10.1016/j.tcb.2016.11.006